KMT2D and neoplasm: No significant difference in tumor growth rate and tumor burden was observed between the wild-type or mutant tumor cells that were engrafted into immune-deficient mice (Supplementary Fig. 2a–d), indicating the dependence of the intact murine immune response for tumor-suppressive effects of MLL3 or MLL4 ablation.